How Semaglutide and Tirzepatide Work for Weight Loss
Both semaglutide and tirzepatide are administered as weekly subcutaneous injections, working by mimicking the hormone GLP-1 to regulate blood sugar and appetite. By activating GLP-1 receptors in the brain, they promote feelings of fullness and reduce appetite significantly. In clinical trials, these effects translated to average weight loss of around 15-20% in participants over the course of treatment.
Semaglutide
The brand name version of semaglutide, Wegovy, was first approved by the FDA in 2021 specifically for chronic weight management in obese or overweight adults. It builds on the success of a lower dose semaglutide, Ozempic, which was already in use for managing Type 2 diabetes.
Tirzepatide
Tirzepatide was approved in 2022 under the brand name Mounjaro. Sometimes referred to as a "super-GLP1," tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors for augmented effects. Clinical trials found it outperformed semaglutide in average weight loss over 72 weeks.
Compounded Semaglutide and Tirzepatide: Understanding Risks
While the FDA-approved versions require prescriptions and oversight by healthcare providers, some compounding pharmacies are offering generic semaglutide and tirzepatide without prescriptions. They market these directly to consumers at lower costs compared to the brand name drugs. However, there are risks involved in using these compounded formulations.
No FDA Regulation or Monitoring
The FDA exerts oversight over branded prescription products like Wegovy and Mounjaro, monitoring their manufacturing, contents, dosing, and side effects once on the market. Compounding pharmacies operate outside this regulation, with no guarantee their products match what the branded versions contain at safe, effective doses.
Inconsistent Production Quality
Compounding involves mixing customized formulations on-demand, raising risks of improper ingredient measurements, purity issues, contamination, inadequate mixing procedures, and dose inconsistencies. Small differences could significantly impact safety and efficacy but may be impossible for consumers to detect on their own.
Side Effects and Drug Interactions
Due to circumventing regulation and healthcare provider supervision, those acquiring compounded semaglutide or tirzepatide lose access to expert medical advice on side effects and drug interactions. This poses risks if underlying conditions or medications should exclude using these powerful weight loss drugs.
Weighing Options for Access to GLP-1 Medications
For obese or overweight individuals struggling with access to branded semaglutide or tirzepatide, speaking to healthcare providers about prescription assistance programs, affordable generic options as they become available, or other covered weight loss medications may be safer alternatives to compounded versions.
Research is still illuminating the long-term efficacy and safety profiles of GLP-1 drugs as weight loss agents. While they hold incredible promise, these powerful medications warrant regulation and expert guidance to balance benefits and risks for each individual patient. Avoiding unapproved compounded formulations helps promote responsible use.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment